NNovo Nordisk Read More Can Novo Nordisk’s GLP-1 Pill Momentum Offset LLY’s Growing Edge?2026-08-16 Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for…
NNovo Nordisk Read More Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says2026-08-05 After a year at the helm, Novo Nordisk’s CEO Maziar Mike Doustdar’s task of closing the gap to…
NNovo Nordisk Read More Novo Nordisk Swallows the Bitter Pill2026-08-05 Novo Nordisk Swallows the Bitter Pill – Moby THE GIST Our analysts just identified a stock with the…
NNovo Nordisk Read More Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook2026-08-04 Novo Nordisk A/S Bagsværd, 4 August 2026 – Financial report for the period 1 January 2026 to 30…
NNovo Nordisk Read More Novo Nordisk A/S Q1 Earnings Call Highlights2026-05-13 Novo Nordisk A/S logo Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better.…
NNovo Nordisk Read More Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 20262026-05-09 Novo Nordisk A/S Bagsværd, Denmark, 6 May 2026 – Financial report for the period 1 January 2026 to…